Preclinical data from an optic nerve crush model showed that ExoPTEN, an exosome-delivered PTEN siRNA, produced a reproducible, dose-dependent functional gain in retinal signaling. In scotopic threshold response electroretinography, both low-dose (4E+8 particles) and high-dose (4E+9 particles) cohorts improved versus saline and naïve exosome controls, with the high-dose group reaching amplitudes comparable to uninjured eyes. Responses exceeding approximately 5 µV were considered detectable; all ExoPTEN-treated eyes surpassed this threshold, with a clearer signal at the higher dose following two extrachoroidal injections post-injury and at one week.
The company coupled this readout with financing and communications moves. NurExone initiated a 30-day acceleration of outstanding September 2023 and January 2024 warrants, which now expire on November 7, 2025. Full exercise would generate roughly C$3.2 million in gross proceeds, with 89% of the instruments held by U.S.-based investors. In parallel, the company extended its agreement with a communications agency through July 2026, adding a capped monthly expense reimbursement, subject to TSXV approval.
Strategically, NurExone is using a functional, dose-responsive preclinical signal to support momentum while it compels near-term warrant conversions. The ONC model is acute and not a perfect surrogate for chronic glaucoma, but the dose dependence and alignment between mechanism and functional recovery strengthen the translational narrative. The inclusion of a naïve exosome arm that underperformed ExoPTEN supports the primacy of the siRNA cargo over the vesicle alone, an important point for regulators scrutinizing mechanisms, CMC controls, and potency assays for exosome-based products. The financing tactic signals an effort to shore up working capital to fund IND-enabling studies, CMC scale-up, and regulatory interactions without pursuing a dilutive primary raise in current market conditions.
For clinical operators, the path forward is specific. An ocular extrachoroidal route requires procedural training, eye-center infrastructure, and standardized ERG, OCT, and potentially VEP capabilities—favoring specialized ophthalmology sites and CROs with retina and optic nerve experience. Translational risk remains material: ONC is a high-signal model, and durable benefit in slowly progressive glaucoma will require careful patient selection, dosing cadence, and clinically meaningful endpoints beyond ERG. On the CMC side, scalable GMP exosome manufacturing, reproducible cargo loading, stability, and fit-for-purpose release testing will be determinative for study starts. Regulators will expect GLP tox, biodistribution, and immunogenicity packages in a relevant species, as well as a clear potency assay that correlates with the observed functional effects.
The near-term watch list is clear. A defined IND-enabling plan with timelines, initiation of GLP toxicology and biodistribution, and evidence of GMP lot readiness will indicate whether the warrant-driven cash infusion translates into program acceleration. Equally important will be clarity on the first clinical indication and design—whether NurExone targets acute optic neuropathies to mirror its model or pushes into glaucoma earlier, the trial will likely begin with unilateral dosing, ascending cohorts, and exploratory functional endpoints layered onto safety. On the capital side, accelerated warrants are sensitive to share price; if exercises lag, runway extension may fall short of IND needs. Expect regulatory dialogue to focus on exosome characterization, cargo integrity, and route-specific safety, with convergence from the FDA and EMA still evolving in this modality. Confirmation of durable functional benefit across dose levels in larger-animal models would de-risk translation and sharpen site and CRO resourcing for a 2026 first-in-human start.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
